These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34321567)

  • 21. Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity.
    Coccia F; Testa M; Guarisco G; Bonci E; Di Cristofano C; Silecchia G; Leonetti F; Gastaldelli A; Capoccia D
    Endocrine; 2020 Mar; 67(3):569-578. PubMed ID: 31858390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic syndrome and liver histology in paediatric non-alcoholic steatohepatitis.
    Manco M; Marcellini M; Devito R; Comparcola D; Sartorelli MR; Nobili V
    Int J Obes (Lond); 2008 Feb; 32(2):381-7. PubMed ID: 18087267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of bariatric surgeries on nonalcoholic fatty liver disease.
    Aldoheyan T; Hassanain M; Al-Mulhim A; Al-Sabhan A; Al-Amro S; Bamehriz F; Al-Khalidi H
    Surg Endosc; 2017 Mar; 31(3):1142-1147. PubMed ID: 27405478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease.
    Maximos M; Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Biernacki D; Suman A; Weber M; Cusi K
    Hepatology; 2015 Jan; 61(1):153-60. PubMed ID: 25145475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPARα gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis.
    Francque S; Verrijken A; Caron S; Prawitt J; Paumelle R; Derudas B; Lefebvre P; Taskinen MR; Van Hul W; Mertens I; Hubens G; Van Marck E; Michielsen P; Van Gaal L; Staels B
    J Hepatol; 2015 Jul; 63(1):164-73. PubMed ID: 25703085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between insulin resistance and liver histology in patients with nonalcoholic steatohepatitis with and without obesity.
    Lazar MV; Eapen M; Nair HR; Siyad I; Gopalakrishna R
    Indian J Gastroenterol; 2020 Feb; 39(1):42-49. PubMed ID: 32222944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD44 is a key player in non-alcoholic steatohepatitis.
    Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
    J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review.
    Souto KP; Meinhardt NG; Ramos MJ; Ulbrich-Kulkzynski JM; Stein AT; Damin DC
    Surg Obes Relat Dis; 2018 Jan; 14(1):66-73. PubMed ID: 29104004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
    Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
    Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 33. A novel and comprehensive mouse model of human non-alcoholic steatohepatitis with the full range of dysmetabolic and histological abnormalities induced by gold thioglucose and a high-fat diet.
    Ogasawara M; Hirose A; Ono M; Aritake K; Nozaki Y; Takahashi M; Okamoto N; Sakamoto S; Iwasaki S; Asanuma T; Taniguchi T; Urade Y; Onishi S; Saibara T; Oben JA
    Liver Int; 2011 Apr; 31(4):542-51. PubMed ID: 21382165
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity.
    Guichelaar MM; Gawrieh S; Olivier M; Viker K; Krishnan A; Sanderson S; Malinchoc M; Watt KD; Swain JM; Sarr M; Charlton MR
    Obesity (Silver Spring); 2013 Sep; 21(9):1935-41. PubMed ID: 23418085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis.
    Musso G; Gambino R; Biroli G; Carello M; Fagà E; Pacini G; De Michieli F; Cassader M; Durazzo M; Rizzetto M; Pagano G
    Am J Gastroenterol; 2005 Nov; 100(11):2438-46. PubMed ID: 16279898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Glucose tolerance alterations and frequency of metabolic syndrome among patients with non alcoholic fatty liver disease].
    Araya Q AV; Valera M JM; Contreras B J; Csendes J A; Díaz J JC; Burdiles P P; Rojas C J; Maluenda G F; Smok S G; Poniachik T J
    Rev Med Chil; 2006 Sep; 134(9):1092-8. PubMed ID: 17167710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adipose type I interferon signalling protects against metabolic dysfunction.
    Wieser V; Adolph TE; Grander C; Grabherr F; Enrich B; Moser P; Moschen AR; Kaser S; Tilg H
    Gut; 2018 Jan; 67(1):157-165. PubMed ID: 28011892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-lymphocyte ratio is independently associated with inflammatory activity and fibrosis grade in nonalcoholic fatty liver disease.
    Khoury T; Mari A; Nseir W; Kadah A; Sbeit W; Mahamid M
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1110-1115. PubMed ID: 30888972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.